Autolus Therapeutics plc (AUTL)

NASDAQ: AUTL · IEX Real-Time Price · USD
2.15
+0.16 (8.04%)
At close: Jan 31, 2023, 4:00 PM
2.09
-0.06 (-2.79%)
After-hours: Jan 31, 2023, 7:50 PM EST
8.04%
Market Cap 372.08M
Revenue (ttm) 2.72M
Net Income (ttm) -163.55M
Shares Out 173.06M
EPS (ttm) -1.85
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,260,963
Open 2.02
Previous Close 1.99
Day's Range 1.96 - 2.15
52-Week Range 1.60 - 5.04
Beta 1.56
Analysts Buy
Price Target 8.64 (+301.86%)
Earnings Date Mar 9, 2023

About AUTL

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 22, 2018
Employees 324
Stock Exchange NASDAQ
Ticker Symbol AUTL
Full Company Profile

Financial Performance

In 2021, AUTL's revenue was $2.33 million, an increase of 35.86% compared to the previous year's $1.72 million. Losses were -$142.10 million, 0.00% more than in 2020.

Financial Statements

Analyst Forecast

According to 17 analysts, the average rating for AUTL stock is "Buy." The 12-month stock price forecast is $8.64, which is an increase of 301.86% from the latest price.

Price Target
$8.64
(301.86% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Autolus Therapeutics announces Board changes

LONDON, Jan. 20, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces two chan...

1 week ago - GlobeNewsWire

Autolus Announces Partial Exercise of Underwriters' Option to Purchase Additional ADSs

LONDON, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced today th...

1 month ago - GlobeNewsWire

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022

LONDON, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces th...

1 month ago - GlobeNewsWire

Autolus Announces Pricing of Public Offering

LONDON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced th...

1 month ago - GlobeNewsWire

Autolus Announces Proposed Public Offering in the United States

LONDON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced th...

1 month ago - GlobeNewsWire

Autolus Therapeutics to Receive $70 Million in Milestone Payments from Blackstone Life Sciences

LONDON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces th...

1 month ago - GlobeNewsWire

Autolus Therapeutics announces pivotal Phase 2 FELIX clinical trial has met primary endpoint at interim analysis

LONDON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces th...

1 month ago - GlobeNewsWire

Autolus Therapeutics to Present Three Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022

LONDON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces th...

3 months ago - GlobeNewsWire

Autolus Therapeutics Reports Third Quarter 2022 Financial Results and Operational Progress

LONDON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced it...

3 months ago - GlobeNewsWire

Autolus Therapeutics to Report Third Quarter 2022 Financial Results on November 3, 2022

LONDON, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced th...

3 months ago - GlobeNewsWire

Moderna exercises option to license proprietary targeting technology from Autolus

- Option exercised on undisclosed immune-oncology target following evaluation period by Moderna -

4 months ago - GlobeNewsWire

Autolus Therapeutics Announces Collaboration with Bristol Myers Squibb for Use of Autolus' Proprietary Safety Switch System

- Bristol Myers Squibb to receive access to Autolus' RQR8 safety switch for use in cell therapy programs -

4 months ago - GlobeNewsWire

Correction - Autolus Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022

In the previous version the link to register for the conference call was incorrect – this press release contains the correct link to register for the call, and replaces the earlier version

6 months ago - GlobeNewsWire

Autolus Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022

LONDON, July 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced th...

6 months ago - GlobeNewsWire

Autolus Therapeutics to Participate in William Blair's Biotech Focus Conference 2022, New York, July 12 – 13, 2022

LONDON, July 06, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces th...

7 months ago - GlobeNewsWire

Autolus Therapeutics Presents Clinical Data Updates at the European Hematology Association Congress

- AUTO4 shows high level of clinical activity with a novel targeting approach for patients with T Cell Lymphoma - AUTO1/22 demonstrates encouraging and durable responses in children ineligible for com...

8 months ago - GlobeNewsWire

Autolus to hold Annual General Meeting (AGM) of Shareholders on Tuesday, June 28, 2022

LONDON, May 31, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today posted notice...

8 months ago - GlobeNewsWire

Autolus Therapeutics to Participate in the Jefferies Healthcare Conference, being held in New York from June 8 – 10, 2022

LONDON, May 27, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces tha...

8 months ago - GlobeNewsWire

Autolus Therapeutics to Present Four Clinical Data Updates at the European Hematology Association Congress

- AUTO4: oral presentation on initial clinical experience in peripheral T cell lymphoma - AUTO1/22: oral presentation on initial experience in r/r pediatric B-cell acute lymphoblastic leukemia - obe-c...

9 months ago - GlobeNewsWire

Autolus Therapeutics Reports First Quarter 2022 Financial Results and Operational Progress

- Conference call to be held on May 5, 2022 at 8:30 am ET/1:30 pm BST - - Conference call to be held on May 5, 2022 at 8:30 am ET/1:30 pm BST -

9 months ago - GlobeNewsWire

Autolus Therapeutics to Present Three Novel Cell Programming Approaches at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting, May 16-19, 2022

Developing cell programming capabilities to improve our pipeline of precise, controlled and highly active products Developing cell programming capabilities to improve our pipeline of precise, controll...

9 months ago - GlobeNewsWire

FDA Grants Regenerative Medicine Advanced Therapy (RMAT) designation to Autolus' CAR T cell therapy, obe-cel, for the treatment of adult B-ALL

LONDON, April 25, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced t...

10 months ago - GlobeNewsWire

Autolus Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call on May 5

LONDON, April 25, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced t...

10 months ago - GlobeNewsWire

Autolus Therapeutics Receives EMA Orphan Medical Product Designation for obe-cel for Treatment of Acute Lymphoblastic Leukemia

LONDON, March 31, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced t...

10 months ago - GlobeNewsWire

Autolus Therapeutics to Participate in Conferences During April 2022

- Wells Fargo Annual Biotech Forum on April 12 and 13 -

11 months ago - GlobeNewsWire